These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35815356)

  • 1. Review and evaluation of vancomycin dosing guidelines for obese individuals.
    Wong S; Reuter SE; Jones GR; Stocker SL
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):323-335. PubMed ID: 35815356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400-600 mg·h/L-Targeted Dosing.
    Zhang T; Krekels EHJ; Smit C; van Dongen EPA; Brüggemann RJM; Knibbe CAJ
    Clin Pharmacokinet; 2024 Jan; 63(1):79-91. PubMed ID: 37971650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
    Lewis SJ; Mueller BA
    J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years.
    Smit C; Goulooze SC; Brüggemann RJM; Sherwin CM; Knibbe CAJ
    AAPS J; 2021 Apr; 23(3):53. PubMed ID: 33839974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies.
    Durand C; Bylo M; Howard B; Belliveau P
    Ann Pharmacother; 2018 Jun; 52(6):580-590. PubMed ID: 29262697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing vancomycin in the super obese: less is more.
    Crass RL; Dunn R; Hong J; Krop LC; Pai MP
    J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
    Waineo MF; Kuhn TC; Brown DL
    J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients.
    Shoji K; Saito J; Nakagawa H; Funaki T; Fukuda A; Sakamoto S; Kasahara M; Momper JD; Capparelli EV; Miyairi I
    Microbiol Spectr; 2021 Oct; 9(2):e0046021. PubMed ID: 34612690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
    Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
    Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
    Kaag D
    Lung Cancer; 2013 Jan; 79(1):54-8. PubMed ID: 23131495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of Vancomycin Population-Predicted Pharmacokinetics with Patient-Specific Pharmacokinetics in Adult Hospitalized Patients: A Case Series.
    Onor IO; Neuliep A; Tran KA; Lambert J; Gillard CJ; Brakta F; Ezebuenyi MC; St James K; Okogbaa JI; Beyl RA
    Drugs R D; 2020 Jun; 20(2):83-93. PubMed ID: 32166646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
    Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
    Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
    [No Abstract]   [Full Text] [Related]  

  • 15. Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.
    Masich AM; Kalaria SN; Gonzales JP; Heil EL; Tata AL; Claeys KC; Patel D; Gopalakrishnan M
    Pharmacotherapy; 2020 Mar; 40(3):211-220. PubMed ID: 31957057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations.
    Brown ML; Hutchison AM; McAtee AM; Gaillard PR; Childress DT
    Am J Health Syst Pharm; 2017 Jul; 74(14):1067-1075. PubMed ID: 28522643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Relevance of a Vancomycin 24 h Area under the Concentration-Time Curve Values Using Different Renal Function Equations in Bayesian Dosing Software.
    Kim HK; Jeong TD
    J Pers Med; 2023 Jan; 13(1):. PubMed ID: 36675782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new population pharmacokinetic model for vancomycin in patients with variable renal function: Therapeutic drug monitoring based on extended covariate model using CKD-EPI estimation.
    Kim DJ; Lee DH; Ahn S; Jung J; Kiem S; Kim SW; Shin JG
    J Clin Pharm Ther; 2019 Oct; 44(5):750-759. PubMed ID: 31228353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.
    Brown DL; Lalla CD; Masselink AJ
    Ther Drug Monit; 2013 Aug; 35(4):443-9. PubMed ID: 23851909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin dosing in chronic high-flux haemodialysis: a systematic review.
    Hui K; Upjohn L; Nalder M; Buising K; Pedagogos E; Nelson C; Kirkpatrick CMJ; Kong DCM
    Int J Antimicrob Agents; 2018 May; 51(5):678-686. PubMed ID: 29284156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.